Helsinn   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tessin Switzerland (1976)

Organization Overview

First Clinical Trial
2004
NCT00090025
First Marketed Drug
2003
palonosetron (aloxi)
First NDA Approval
2003
palonosetron (aloxi)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HELSINN | Helsinn Healthcare SA | HELSINN HLTHCARE | Helsinn Therapeutics (U.S.), Inc

Indications

Approved Indications


 

Postoperative Nausea and Vomiting

Vomiting

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 3)

Biliary Tract Neoplasms (Phase 3)

Cachexia (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Congenital Abnormalities (Phase 2)

Diarrhea (Phase 2)

Fatigue (Phase 2)

Genital Neoplasms, Female (Phase 3)

Ileus (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Nausea (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Postoperative Nausea and Vomiting (Phase 3)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Vomiting (Phase 3)

Wasting Syndrome (Phase 3)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 32